| Literature DB >> 25330370 |
Qiao-Ting Chao1, Tai-Fen Lee2, Shih-Hua Teng3, Li-Yun Peng1, Ping-Hung Chen1, Lee-Jene Teng2, Po-Ren Hsueh4.
Abstract
We assessed the accuracy of species-level identification of two commercially available matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) systems (Bruker Biotyper and Vitek MS) and two conventional phenotypic methods (Phoenix 100 YBC and Vitek 2 Yeast ID) with that of rDNA gene sequencing analysis among 200 clinical isolates of commonly encountered yeasts. The correct identification rates of the 200 yeast isolates to species or complex (Candida parapsilosis complex, C. guilliermondii complex and C. rugosa complex) levels by the Bruker Biotyper, Vitek MS (using in vitro devices [IVD] database), Phoenix 100 YBC and Vitek 2 Yeast ID (Sabouraud's dextrose agar) systems were 92.5%, 79.5%, 89%, and 74%, respectively. An additional 72 isolates of C. parapsilosis complex and 18 from the above 200 isolates (30 in each of C. parapsilosis, C. metapsilosis, and C. orthopsilosis) were also evaluated separately. Bruker Biotyper system could accurately identify all C. parapsilosis complex to species level. Using Vitek 2 MS (IVD) system, all C. parapsilosis but none of C. metapsilosis, or C. orthopsilosis could be accurately identified. Among the 89 yeasts misidentified by the Vitek 2 MS (IVD) system, 39 (43.8%), including 27 C. orthopsilosis isolates, could be correctly identified Using the Vitek MS Plus SARAMIS database for research use only. This resulted in an increase in the rate of correct identification of all yeast isolates (87.5%) by Vitek 2 MS. The two species in C. guilliermondii complex (C. guilliermondii and C. fermentati) isolates were correctly identified by cluster analysis of spectra generated by the Bruker Biotyper system. Based on the results obtained in the current study, MALDI-TOF MS systems present a promising alternative for the routine identification of yeast species, including clinically commonly and rarely encountered yeast species and several species belonging to C. parapsilosis complex, C. guilliermondii complex, and C. rugosa complex.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25330370 PMCID: PMC4199611 DOI: 10.1371/journal.pone.0109376
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Identification results of 200 clinical isolates of yeasts by two commercial identification systems (Phoenix and Vitek 2 systems) and two MALDI-TOF MS systems (Bruker Biotyper and Vitek MS).
| Species | No. of isolates tested (no. of BD challenge isolates) | No. (%) of isolates with identical identification results compared with those by gene sequencing analysis | |||||
| Phoenix 100 YBC | Vitek 2 Yeast ID | MALDI-TOF MS | |||||
| BAP | SDA | BAP | SDA | Bruker Biotyper | Vitek MS (CU database) | ||
|
|
|
|
|
|
|
|
|
|
| 19 (9) | 19 (100) | 19 (100) | 18 (94.7) | 19 (100) | 19 (100) | 19 (100) |
|
| 19 (10) | 19 (100) | 19 (100) | 19 (100) | 19 (100) | 19 (100) | 19 (100) |
|
| 18 (7) | 18 (100) | 18 (100) | 18 (100) | 18 (100) | 18 (100) | 6 (33.3) |
|
| 18 (7) |
| 16 (88.9) |
|
| 18 (100) |
|
|
| 17 (7) | 16 (94.1) | 17 (100) | 17 (100) | 17 (100) | 17 (100) | 17 (100) |
|
| 14 (8) | 13 (92.9) | 14 (100) | 10 (71.4) | 13 (92.9) | 14 (100) | 14 (100) |
|
| 6 (4) | 6 (100) | 5 (83.3) | 6 (100) | 5 (83.3) | 6 (100) | 6 (100) |
|
| 6 (1) | 6 (100) | 6 (100) | 6 (100) | 5 (83.3) | 6 (100) | 6 (100) |
|
| 4 (1) | 3 (75) | 4 (100) | 3 (75) | 3 (75) | 4 (100) | 3 (75) |
|
| 3 (0) | 2 (66.7) | 3 (100) | 3 (100) | 3 (100) | 3 (100) | 3 (100) |
|
| 1 (0) | 1 (100) | 1 (100) | 0 (0) | 0 (0) | 1 (100) | 0 (0) |
|
| 3 (3) | 3 (100) | 3 (100) | 2 (66.7) | 2 (66.7) | 3 (100) | 3 (100) |
|
| 2 (2) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) |
|
| 2 (2) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) |
|
| 2 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (100) | 0 (0) |
|
| 2 (1) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) |
|
| 1 (1) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) |
|
| 1 (0) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) |
|
| 1 (0) | 0 (0) | 0 (0) | 1 (100) | 1 (100) | 1 (100) | 1 (100) |
|
| 1 (1) | 1 (100) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 1 (100) |
|
| 1 (1) | 0 (0) | 1 (100) | 0 (0) | 1 (100) | 1 (100) | 1 (100) |
| C. | 1 (1) | 1 (100) | 1 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
|
| 1 (1) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) |
|
| 1 (0) | 0 (0) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) |
| C. | 2 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (50) | 1 (50) |
|
|
|
|
|
|
|
|
|
|
| 17 (7) | 17 (100) | 17 (100) | 14 (82.4) | 15 (88.2) | 17 (100) | 13 (76.5) |
|
| 1 (1) | 1 (100) | 1 (100) | 1 (100) | 0 (0) | 0 (0) | 0 (0) |
|
| 1 (1) | 1 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) |
|
| 1 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
|
| 13 (2) | 10 (76.9) | 10 (76.9) | 0 (0) | 0 (0) | 10 (76.9) | 10 (76.9) |
|
|
|
|
|
|
|
|
|
|
| 6 (0) | 4 (66.7) | 6 (100) | 6 (100) | 5 (83.3) | 5 (83.3) | 5 (83.3) |
|
| 1 (1) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 1 (100) | 0 (0) |
|
| 1 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
|
|
|
|
|
|
|
|
|
|
| 1 (0) | 0 (0) | 0 (0) | 1 (100) | 1 (100) | 1 (100) | 1 (100) |
|
| 1 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
|
| 5 (4) | 5 (100) | 5 (100) | 5 (100) | 5 (100) | 5 (100) | 5 (100) |
|
| 2 (2) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 0 (0) |
|
| 2 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (100) | 0 (0) |
|
| 2 (1) | 1 (50) | 1 (50) | 0 (0) | 0 (0) | 2 (100) | 0 (0) |
|
| 1 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
|
| 1 (1) | 0 (0) | 0 (0) | 1 (100) | 1 (100) | 0 (0) | 0 (0) |
|
| 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
|
| 1 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
|
|
|
|
|
|
|
|
|
Note. BAP: trypticase soy agar with 5% sheep blood agar plates. SDA: Sabouraud dextrose agar. CU: clinical use.
Identification results of clinical isolates of yeasts by two commercial identification systems (Phoenix and Vitek 2 systems) and two MALDI-TOF MS systems (Bruker Biotyper and Vitek MS).
| Species | No. of isolates tested | Species with misidentified results by indicated method compared with those by gene sequencing analysis (no. of isolates) | |||||
| Phoenix 100 YBC | Vitek 2 Yeast ID | MALDI-TOF MS | |||||
| BAP | SDA | BAP | SDA | Biotyper | Vitek MS (CU database) | ||
|
| |||||||
|
| 19 | - | - | C. | - | - | - |
|
| 18 | Unidentified (1) | C. |
|
| - |
|
|
| 17 | C. | - | - | - | - | - |
|
| 14 | C. | - |
|
| - | - |
|
| 6 | - |
| - |
| - | - |
|
| 6 | - | - | - | C. | - | - |
|
| 1 | No ID (1) | - |
|
| - | - |
|
| 1 | - | - |
|
| - | No ID (1) |
|
| 3 | - | - |
|
| - | - |
|
| 2 |
|
|
|
| - |
|
|
| 1 |
|
| - | - | - | - |
|
| 1 | - | No ID (1) | Unidentified (1) | No ID (1) | - | - |
|
| 1 | Unidentified (1) | - |
| - | - | - |
| C. | 1 | - | - |
| No ID (1) |
|
|
|
| 1 |
| - | - | - | - | - |
| C. | 2 |
|
|
|
|
|
|
|
|
| ||||||
|
| 17 | - | - |
| C. | - | No ID (4) |
|
| 1 | - | - | - | C. | No ID (1) | No ID (1) |
|
| 1 | - | No ID (1) |
|
|
|
|
|
| 1 | No ID (1) |
| S. |
| No ID (1) |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
| 6 |
| - | - |
| No ID (1) |
|
|
| 1 | - | - | - | - | - |
|
|
| 1 | No ID (1) | No ID (1) |
|
|
|
|
|
|
| ||||||
|
| 1 |
|
| - | - | - | - |
|
| 1 |
|
|
|
| No ID (1) | No ID (1) |
|
|
| ||||||
|
| 2 | - | - | - | - | - | No ID (2) |
|
| 2 |
|
|
|
| - |
|
|
| 2 |
| S. cerevisiae (1) |
|
| - |
|
|
| 1 |
|
|
|
|
| No ID (1) |
|
| 1 |
|
| - | - |
|
|
|
| 1 | No ID (1) | No ID (1) |
|
| No ID (1) | No ID (1) |
|
| 1 |
|
|
|
|
|
|
Note. BAP: trypticase soy agar with 5% sheep blood agar plates. IVD: in vitro devices. No ID, no identification. SDA: Sabouraud dextrose agar.
Identification results using two Vitek MS databases, clinical use (CU) and Vitek MS Plus SARAMIS for research use only (RUO) for 89 yeast isolates initially misidentified or with no identification (No ID).
| Species (identified by gene sequencing analysis) | No. of isolates | Vitek MS by IVD database (% probability) | Vitek MS Plus SARAMIS for RUO (% probability) |
|
| 27 | No ID | No ID |
| 3 | No ID |
| |
|
| 27 | No ID |
|
| 2 |
|
| |
| 1 | No ID | No ID | |
|
| 1 |
|
|
|
| 1 | No ID |
|
|
| 1 |
|
|
| 1 |
|
| |
| C. | 1 |
|
|
| C. | 1 |
|
|
|
| 3 | No ID | No ID |
| 1 | No ID |
| |
|
| 1 | No ID | No ID |
|
| 1 |
| No ID |
|
| 1 |
| No ID |
| 2 | No ID | No ID | |
|
| 1 |
| No ID |
|
| 1 |
| No ID |
|
| 1 |
| No ID |
|
| 1 | No ID |
|
|
| 1 | No ID | No ID |
| 1 | No ID |
| |
|
| 2 |
|
|
|
| 1 | No ID |
|
| 1 |
|
| |
|
| 1 | No ID | No ID |
|
| 1 |
|
|
|
| 1 | No ID | No ID |
|
| 1 |
|
|
Note. Species typed in bold face indicate correct identification using Vitek MS Plus SARAMIS database for RUO for yeast isolates which were initially misidentified or reported no ID.
Figure 1Cluster analysis of MALDI-TOF Bruker Biotyper results for the 90 isolates of C. parapsilosis complex.
A. Three clusters of C. parapsilosis complex spectra, i.e., cluster 1 (C. parapsilosis), cluster 2 (C. orthopsilosis), and cluster 3 (C. metapsilosis). B. The 10 peaks used to define cluster 1 (C. parapsilosis), cluster 2 (C. orthopsilosis), and cluster 3 (C. metapsilosis), which were generated by ClinProTools with the genetic algorithm, are 3380.19 m/z, 4,993.07 m/z, 5383.92 m/z, 5411.78 m/z, 5582.74 m/z, 5668.24 m/z, 7014.07 m/z, 7070.65 m/z, 7212.67 m/z, and 7326,88 m/z. Three signals 4,993.07 m/z, 5411.78 m/z, and 7070.65 m/z were observed only in the spectrum for cluster 1 (all were C. parapsilosis) spectra, three signals 3380.19 m/z, 5383.92 m/z, and 7014.07 m/z were observed only in the spectrum for cluster 2 (all were C. orthopsilosis) spectra, and four signals 5582.74 m/z, 5668.24 m/z, 7212.67 m/z, and 7326.88 m/z were observed only in the spectrum for cluster 3 (all were C. metapsilosis) spectra. The absolute intensities of the ions are shown on the y axis, and the masses (m/z) of the ions are shown on the x axis. The m/z values represent the mass-to-charge ratio. (C) Distribution of identification score values among three species of C. parapsilosis complex by MALDI-TOF Bruker Biotyper system.
Figure 2Cluster analysis of MALDI-TOF Bruker Biotyper results for the 18 isolates of C. guilliermondii complex.
A. Two clusters of C. guilliermondii complex spectra, i.e., cluster I (C. fermentati) and cluster II (C. guilliermondii). B. The five peaks used to define cluster I (C. fermentati) and cluster II (C. guilliermondii), which were generated by ClinProTools with the genetic algorithm, are five signals, i.e., 3181.57 m/z, 3359.10 m/z, 5218.25 m/z, 6717.05 m/z, and 6732.14 m/z. The signals of 3181.57 m/z, 5218.25 m/z, and 6732.14 m/z were observed in cluster I spectra but not in cluster II spectra, and those of 3359.10 m/z and 6717.05 m/z were observed in cluster II spectra but not in cluster I spectra. The absolute intensities of the ions are shown on the y axis, and the masses (m/z) of the ions are shown on the x axis. The m/z values represent the mass-to-charge ratio.
Figure 3Spectra of C. rugosa complex isolates.
A. Two groups of C. rugosa complex spectra, i.e., group 1 (C. rugosa) and group II (C. pararugosa), generated by MALDI-TOF Bruker Biotyper results. B. The six characteristic peaks used to differentiate group I (C. rugosa) and group II (C. pararugosa): i.e. 3050.6 m/z, 3462.3 m/z, 5409.0 m/z, 6102.2 m/z were observed in group I spectra but not in group II spectra, and those of 3131.9 m/z and 6363.4 m/z were observed in group II spectra but not in group I spectra. The absolute intensities of the ions are shown on the y axis, and the masses (m/z) of the ions are shown on the x axis. The m/z values represent the mass-to-charge ratio.